I am a
Home I AM A Search Login

Papers of the Week


Papers: 13 Mar 2021 - 19 Mar 2021


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Mar 17


Eur J Neurol

Partial and non responders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal preventive treatment: a real-world evidence study.

Authors

Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrús M, Pozo-Rosich P
Eur J Neurol. 2021 Mar 17.
PMID: 33730441.

Abstract

Monoclonal antibodies targeting CGRP or its receptor (anti-CGRP mAbs) are proven to be effective treatments in migraine prevention. Real-world evidence studies assessing their efficacy are scarce.